BioMérieux Shares Hit Lowest Since 2019, RSI Drops to 17
The stock of the Lyon-based in vitro diagnostics specialist continues its downward spiral. In mid-afternoon on Wednesday, April 29, 2026, the stock fell by 0.43% to €69.50, after having touched €69.25 during the session, its lowest level since 2019. The company's market capitalization has now declined by 40% over the year.
BioMérieux's stock recorded a new session low at €69.25, falling below the previous low of €69.30 set in 2019. The stock thus sinks below its technical support threshold identified at €70.95, a level whose breach paves the way to uncharted territory since pre-Covid times. Over the past seven days, the decline reached 23.29%, while the quarterly performance stands at -30.01%. This contrasts sharply with the 200-day moving average, which is at €107.43, more than 35% above the current price. Meanwhile, the CAC 40 only lost 0.18% in the session, to 8,089.30 points, highlighting the marked underperformance of the stock. Within the healthcare sector, European comparables also moved into negative territory (Sanofi down by 0.75% and UCB by 1.14%), but to a lesser extent compared to the drop of the Lyon-based group.
A Technical Configuration in Extreme Oversold
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The indicators reflect a state of tension rarely seen on the stock. The 14-day RSI stands at 17, well below the usual oversold threshold of 30. This indicator, which measures the speed and magnitude of price changes, signals a statistically significant bearish excess. Concurrently, the price of €69.50 is trading below the lower Bollinger Band set at €77.18, confirming the abnormal deviation of the stock from its recent average. The upper band, at €101.04, illustrates the extent of the corridor traversed in a few weeks. The financial calendar offers few immediate catalysts: the next major deadline is set for July 28, 2026, with the publication of the half-year results. Until then, the stock will have to contend with a macroeconomic environment burdened by the surge in Brent crude above $114 a barrel and geopolitical tensions in the Middle East, weighing on all European indices.
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
